Effect of subcutaneous insulin detemir on glucose flux and lipolysis during hyperglycaemia in people with type 1 diabetes

What Was Tested

The paper reports a study of Insulin Detemir and NPH Insulin (isophane), published as a randomized controlled trial.

To investigate, using a novel non-steady-state protocol, the differential effects of subcutaneous (s.c.) detemir and NPH insulin on glucose flux and lipid metabolism after insulin withdrawal.

Who Took Part

The abstract describes 11 participants taking part.

The age groups tagged for this paper are adults, men only.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Insulin Detemir and who got the comparison, which limits bias.

Stable isotopes of glucose and glycerol were infused intravenously throughout the study protocol.

What Was Measured

The subject headings attached to it are Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Glycerol, Hyperglycemia and Hypoglycemic Agents.

Author keywords: insulin analogues, insulin therapy, liver and type 1 diabetes.

What This Means in Plain Language

The paper is a randomized study of Insulin Detemir and NPH Insulin (isophane) in 11 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Detemir compound page and the NPH Insulin (isophane) compound page, all human trials.